MX2013007645A - Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf) obtenidos mediante mutagenesis de regiones variables. - Google Patents
Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf) obtenidos mediante mutagenesis de regiones variables.Info
- Publication number
- MX2013007645A MX2013007645A MX2013007645A MX2013007645A MX2013007645A MX 2013007645 A MX2013007645 A MX 2013007645A MX 2013007645 A MX2013007645 A MX 2013007645A MX 2013007645 A MX2013007645 A MX 2013007645A MX 2013007645 A MX2013007645 A MX 2013007645A
- Authority
- MX
- Mexico
- Prior art keywords
- vegf
- mutagenesis
- growth factor
- antibodies
- human
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1021—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against cytokines, e.g. growth factors, VEGF, TNF, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente invención revela anticuerpos recombinantes humanos que reconocen el Factor de Crecimiento del Endotelio Vascular-A (VEGF-A) humano, bloquean su interacción con el receptor VEGFR2, e interfieren con sus efectos proliferativos in vitro y pro-angiogénicos in vivo; estos anticuerpos identifican un epítope en el VEGF-A humano diferente a cualquier otro reportado antes y se obtuvieron combinando una misma región variable de cadena ligera de inmunoglobulinas, con otras tres de cadena pesada; los anticuerpos se obtuvieron mediante mutagénesis de regiones variables de inmunoglobulinas humanas, y pueden emplearse para la inmunoterapia de entidades patológicas cuyo curso esté asociado al aumento de la vasculatura, tales como la degeneración macular asociada a la edad, el cáncer y otras.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU20100264A CU23895B1 (es) | 2010-12-28 | 2010-12-28 | Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf) obtenidos mediante mutagénesis de regiones variables |
PCT/CU2011/000009 WO2012089176A1 (es) | 2010-12-28 | 2011-12-26 | Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf) obtenidos mediante mutagenesis de regiones variables |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2013007645A true MX2013007645A (es) | 2013-12-02 |
MX344915B MX344915B (es) | 2017-01-10 |
Family
ID=45768110
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013007645A MX344915B (es) | 2010-12-28 | 2011-12-26 | Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf) obtenidos mediante mutagenesis de regiones variables. |
Country Status (18)
Country | Link |
---|---|
US (1) | US9505830B2 (es) |
EP (1) | EP2662388B1 (es) |
JP (1) | JP6082698B2 (es) |
KR (1) | KR101896108B1 (es) |
CN (1) | CN103370336B (es) |
AR (1) | AR084618A1 (es) |
AU (1) | AU2011352474B2 (es) |
BR (1) | BR112013016684A2 (es) |
CA (1) | CA2823233C (es) |
CU (1) | CU23895B1 (es) |
ES (1) | ES2687183T3 (es) |
MX (1) | MX344915B (es) |
MY (1) | MY166550A (es) |
RU (1) | RU2557309C2 (es) |
TW (1) | TWI555757B (es) |
UY (1) | UY33844A (es) |
WO (1) | WO2012089176A1 (es) |
ZA (1) | ZA201305031B (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
CL2014002941A1 (es) * | 2014-10-30 | 2015-04-06 | Univ Concepcion | Moléculas polipeptídicas contra el factor de crecimiento del endotelio vascular (vegf) |
RU2744860C2 (ru) | 2015-12-30 | 2021-03-16 | Кодиак Сайенсиз Инк. | Антитела и их конъюгаты |
EP3731865A1 (en) | 2017-12-29 | 2020-11-04 | F. Hoffmann-La Roche AG | Method for improving vegf-receptor blocking selectivity of an anti-vegf antibody |
WO2020127864A1 (en) * | 2018-12-21 | 2020-06-25 | F. Hoffmann-La Roche Ag | Method for improving inhibition of vegf-binding to vegf-r1 of an anti-vegf antibody |
AU2020364071A1 (en) | 2019-10-10 | 2022-05-26 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
CU20210101A7 (es) | 2021-12-15 | 2023-07-12 | Ct Ingenieria Genetica Biotecnologia | Polipéptidos que se unen a factores de crecimiento proangiogénicos |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2150262C (en) | 1992-12-04 | 2008-07-08 | Kaspar-Philipp Holliger | Multivalent and multispecific binding proteins, their manufacture and use |
US5730977A (en) | 1995-08-21 | 1998-03-24 | Mitsui Toatsu Chemicals, Inc. | Anti-VEGF human monoclonal antibody |
US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
CU23636A1 (es) * | 2006-11-01 | 2011-03-21 | Ct Ingenieria Genetica Biotech | Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf) |
WO2008105248A1 (ja) | 2007-02-27 | 2008-09-04 | Nikon Corporation | ズームレンズと、これを有する光学装置 |
US9209965B2 (en) | 2014-01-14 | 2015-12-08 | Microsemi Semiconductor Ulc | Network interface with clock recovery module on line card |
-
2010
- 2010-12-28 CU CU20100264A patent/CU23895B1/es active IP Right Grant
-
2011
- 2011-12-26 JP JP2013546584A patent/JP6082698B2/ja not_active Expired - Fee Related
- 2011-12-26 BR BR112013016684A patent/BR112013016684A2/pt not_active Application Discontinuation
- 2011-12-26 MX MX2013007645A patent/MX344915B/es active IP Right Grant
- 2011-12-26 CA CA2823233A patent/CA2823233C/en not_active Expired - Fee Related
- 2011-12-26 AU AU2011352474A patent/AU2011352474B2/en not_active Ceased
- 2011-12-26 RU RU2013134983/10A patent/RU2557309C2/ru active
- 2011-12-26 EP EP11820879.2A patent/EP2662388B1/en active Active
- 2011-12-26 MY MYPI2013701133A patent/MY166550A/en unknown
- 2011-12-26 WO PCT/CU2011/000009 patent/WO2012089176A1/es active Application Filing
- 2011-12-26 KR KR1020137019847A patent/KR101896108B1/ko active IP Right Grant
- 2011-12-26 ES ES11820879.2T patent/ES2687183T3/es active Active
- 2011-12-26 CN CN201180066879.4A patent/CN103370336B/zh not_active Expired - Fee Related
- 2011-12-26 US US13/976,060 patent/US9505830B2/en active Active
- 2011-12-27 TW TW100148878A patent/TWI555757B/zh not_active IP Right Cessation
- 2011-12-27 AR ARP110104967A patent/AR084618A1/es unknown
- 2011-12-28 UY UY0001033844A patent/UY33844A/es not_active Application Discontinuation
-
2013
- 2013-07-04 ZA ZA2013/05031A patent/ZA201305031B/en unknown
Also Published As
Publication number | Publication date |
---|---|
TWI555757B (zh) | 2016-11-01 |
KR101896108B1 (ko) | 2018-09-10 |
EP2662388B1 (en) | 2018-08-22 |
CU23895B1 (es) | 2013-05-31 |
MY166550A (en) | 2018-07-16 |
CA2823233C (en) | 2020-06-09 |
US9505830B2 (en) | 2016-11-29 |
TW201305203A (zh) | 2013-02-01 |
RU2557309C2 (ru) | 2015-07-20 |
BR112013016684A2 (pt) | 2017-06-06 |
AU2011352474B2 (en) | 2017-02-16 |
JP6082698B2 (ja) | 2017-02-15 |
ZA201305031B (en) | 2014-03-26 |
MX344915B (es) | 2017-01-10 |
RU2013134983A (ru) | 2015-02-10 |
CN103370336B (zh) | 2015-11-25 |
EP2662388A1 (en) | 2013-11-13 |
CU20100264A7 (es) | 2012-07-31 |
JP2014504498A (ja) | 2014-02-24 |
CN103370336A (zh) | 2013-10-23 |
AR084618A1 (es) | 2013-05-29 |
AU2011352474A1 (en) | 2013-08-15 |
US20140086829A1 (en) | 2014-03-27 |
WO2012089176A1 (es) | 2012-07-05 |
ES2687183T3 (es) | 2018-10-24 |
UY33844A (es) | 2012-07-31 |
KR20140019316A (ko) | 2014-02-14 |
CA2823233A1 (en) | 2012-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2013007645A (es) | Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf) obtenidos mediante mutagenesis de regiones variables. | |
CY1124681T1 (el) | Διειδικα αντισωματα anti-vegf/anti-ang-2 και η χρηση τους στην αγωγη οφθαλμικων αγγειακων νοσων | |
EP2579895A4 (en) | ANTI-VEGF ANTIBODIES AND USES THEREOF | |
CY1124028T1 (el) | Συνθεσεις και μεθοδοι για τα αντισωματα που στοχευουν την ερο | |
MX2017013471A (es) | Metodo de secuenciamiento, determinacion, apareamiento y validacion de agentes terapeuticos y antigenos especificos de enfermedades. | |
NZ738979A (en) | Pd-1 antibodies | |
MX2021010471A (es) | Anticuerpos y conjugados de anticuerpo y farmaco anti-egfr. | |
PH12015501493B1 (en) | Anti-pdgfr-beta antibodies and uses thereof | |
CA2886433C (en) | Human monoclonal anti-pd-l1 antibodies and methods of use | |
MX347515B (es) | Agentes que se unen al receptor encrespado y usos de los mismos. | |
UA118029C2 (uk) | Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування | |
EA201791693A1 (ru) | Гетеродимерные иммуноглобулины | |
NZ706377A (en) | Il-6 antagonists and uses thereof | |
IN2014DN08163A (es) | ||
MX2016008098A (es) | Anticuerpos biespecificos del receptor 2 de factor de crecimiento ipidermico himano (her2) y metodo de uso. | |
NZ706189A (en) | Monoclonal antibodies to growth and differentiation factor 15 (gdf-15) | |
MX358728B (es) | Composiciones de anticuerpos pan-receptor del factor de crecimiento epidermico humano (pan-her) humanizados. | |
EA201491569A1 (ru) | МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С СИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ | |
EA201791393A2 (ru) | АНТИТЕЛА К ErbB3 И ИХ ПРИМЕНЕНИЕ | |
EA201591113A1 (ru) | Антитела против антигена 2 дендритных клеток крови и их применение | |
MX346500B (es) | Metodos y composiciones para inmunoterapia para enfermedad neural. | |
EA201492163A1 (ru) | ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К TrkA, СОДЕРЖАЩИЕ АМИНОКИСЛОТНЫЕ ЗАМЕНЫ | |
PH12015500752A1 (en) | Her3 antigen binding proteins binding to the beta-hairpin of her3 | |
WO2014062659A3 (en) | Methods of treating ocular diseases | |
PH12015500751A1 (en) | Anti-her3/her4 antigen binding proteins binding to the beta-hairpin of her3 and beta-hairpin of her4 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |